| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Inflammatory myopathies associated with anti-mitochondrial antibodies may avoid or wean off noninvasive positive pressure ventilation. The prevalence of anti-mitochondrial antibodies in patients with respiratory disease is not known, so we conducted a survey. In addition, we examined whether hypercarbonemic patients with respiratory disease have a higher prevalence of anti-mitochondrial antibody positivity. The positive rate of AMA-M2 in patients with respiratory disease was 4.4%. AMA-M2 positivity was as high as 11.1% in patients with hypercarbonemia. Inflammatory myopathies associated with anti-mitochondrial antibodies may be more likely to occur among hypercarbonemia and sleep-related hypoventilation cases. It was suggested that it could contribute to avoidance or withdrawal of noninvasive positive pressure ventilation.
|
